Divisions

Positioned to Grow the Psychedelics Market

NeonMind has two business divisions focused on complementary aspects of the psychedelics market: a pharmaceutical division developing psilocybin-based drug candidates targeting obesity and weight management, and a medical services division which will be launching specialty mental health clinics in Canada that incorporate innovative, evidence-backed validated interventional psychiatry treatments for mood and anxiety disorders.

Pharmaceutical Division - Drug Development Pioneers

Pharmaceutical Division - Drug Development Pioneers

NeonMind is pursuing two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional drug candidate, NEO-002, which employs low-dose psilocybin to control appetite.

NeonMind has partnered with leaders in the field of pharmaceutical research and development to advance its lead obesity drug candidates into human clinical trials.

Pharmaceutical Division
Specialty Clinics - Innovative Interventional Psychiatry Treatments

Specialty Clinics - Innovative Interventional Psychiatry Treatments

Our medical services division is preparing to launch NeonMind-branded specialty mental health clinics across Canada, offering evidence-backed validated interventional psychiatry treatments tailored to local market needs. The Company has built a leading scientific advisory board, globally renowned for their expertise in practicing interventional psychiatry to treat mood and anxiety disorders. A medical services platform entrenched in the growing psychedelic sector, by improving access to validated treatments and incorporating the promising pipeline of psychedelic treatments as they are approved.

Medical Services